Clinical observation of endostar® combined with chemotherapy in advanced colorectal cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 3087-3090

  Xu, Hong Xia ^a   Huang, Xin En ^a   Qian, Zhi Ying ^a   Xu, Xia ^a   Li, Ying ^a   Li, Cheng Guang ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Advanced colorectal cancer; chemotherapy; China; Endostar

Indexed keywords

EID: 84863330259     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Center for Statistic Information Ministry of Health, P.R. China (2002). Statistic bulletin of national health development in 2001. China Pharmaceutical Technology Exchange, 4, 4-7.
2. Fernando NH, Hurwitz HI (2004). Targeted therapy of colorectal cancer: clinical experience with Bevacizumab.The Oncologist, 9, 11-8.
3. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
4. Folkman J (2002).Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8.
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al(2007). Bevacizumab in combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results From the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44
6. Huang XE, Hirose K, Wakai K, et al(2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
7. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
8. Ki YC, Jinru S, Nancy E, et al(2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23, 1803-10.
9. Li Y, Huang XE, Yan PW, et al(2010). Efficacy and safety of Endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.
10. Jemal A, Murray T, Ward E, et al(2005). Cancer statistics. CA Cancer J Clin, 55, 10-30.
11. Loupakis F, Bria E, Vaccaro V, et al(2010). Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res, 29, 58.
12. Miller AB, Hoogstraten B, Staquet M, et al(1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
13. Ooyama A, Oka T, Zhao HY, et al(2008). Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett, 267, 26-36.
14. Saltz LB, Clarke S, Díaz-Rubio E, et al(2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-9.
15. Tebbutt NC, Wilson K, Gebski VJ, et al(2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol, 28, 3191-8.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al(2000). New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.
17. Wang Y, Fei D,Vanderlaan M, et al(2004). Biological activity of bevacizumab: a humanized anti-VEGF antibody in vitro. Angiogenesis, 7, 335-45.
18. Wang JW, Sun Y, Liu YY, et al(2005). Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chinese J Lung Cancer, 8 , 4283-90.
19. Wang TB, Dong WG, Li ZT et al(2005). The effect of recombinant human endostatin combined with 5-Fluorouracil on the growth of xenografted gastric cancer in nude mouse. Chinese J General Surgery, 20, 307-9.
20. Wen QL, Meng MB, Yang B, et al(2009). Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci, 100, 1510-9.
21. Yang L, Wang JW, Tang ZM, et al(2004). A phase clinical trial for recombinant human endostatin. Chinese New Drugs J, 1, 548-53.
22. Yao CY, Huang XE, Tang JH, et al(2010). Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
23. Ying-xia Chen, Shu-kui Qin, Xiu-feng Liu, et al(2009). Clin ical study of rh-endostatin combined with chemotherapy for advanced gastric cancer. Chinese Clin Oncol, 14, 327-31.
24. Yuan X, Zhang DS, Yuan ZY, et al(2007). Endostar combined with chemotherapy in the treatment of HER-2 negative breast cancer. Oncology Progress, 6, 604-7.
25. Zhang RR, Li MS, Tang SY, et al(2009). Clinical study of Endostar combined with chemotherapy for advanced colorectal cancer. Shenzhen J Integrated Traditional Chinese Western Medicine, 6, 339-41.
26. Zhang DW, Li H L, Yao Q, et al(2010). The synergistic effect of recombinant human endost at in (YH-16 ) combined with oxaliplat in on human colorectal carcinoma. J Int Med Res, 38, 111-26.